Cardiovascular risk stratification in familial hypercholesterolaemia

Area of Science:

• Cardiology
• Genetics
• Preventive Medicine

Background:

• Familial hypercholesterolaemia (FH) is an autosomal-dominant disorder common in Europe, leading to elevated low-density lipoprotein cholesterol and increased risk of premature coronary heart disease (CHD).
• Current clinical guidelines lack consensus on predicting future coronary events or screening for subclinical atherosclerosis in asymptomatic FH patients.
• Traditional coronary heart disease risk scores are insufficient for risk stratification in young, asymptomatic individuals diagnosed with FH through family screening.

Purpose of the Study:

• To address the need for improved risk prediction and screening strategies for patients with Familial hypercholesterolaemia.
• To evaluate the utility of non-invasive imaging techniques and novel biomarkers for identifying high-risk FH individuals.
• To inform the development of better screening programs for prioritizing treatment with emerging therapies like PCSK9 inhibitors.

Main Methods:

• Review of current clinical guidelines and risk assessment tools for Familial hypercholesterolaemia.
• Discussion of the limitations of traditional coronary heart disease risk scores in young FH populations.
• Exploration of the potential of non-invasive imaging (e.g., carotid intima-media thickness) and new cardiovascular biomarkers.

Main Results:

• Traditional risk scores like the Framingham score are insufficient for predicting coronary events in young, asymptomatic FH patients.
• Family screening identifies many young individuals with FH who are clinically asymptomatic but at high risk.
• Non-invasive imaging methods may offer more reliable risk assessment in FH patients.

Conclusions:

• There is a critical need for enhanced screening programs and more accurate risk prediction tools for Familial hypercholesterolaemia.
• Novel imaging techniques and biomarkers show promise but require further validation in prospective trials.
• Improved strategies are essential for identifying high-risk FH patients for timely intervention, especially with new therapeutic options available.